VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
Steven Sher(The Ohio State University), Rosa Lapalombella(The Ohio State University)
Cited by 37
Related Papers
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
|Nature Communications|2023|32
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia
|Nature Communications|2021|9